STOCK TITAN
  1. Home
  2. News
  3. HUGE

FSD Pharma Inc. Class B Subordinate Voting Shares - HUGE STOCK NEWS

Welcome to our dedicated page for FSD Pharma Class B Subordinate Voting Shares news (Ticker: HUGE), a resource for investors and traders seeking the latest updates and insights on FSD Pharma Class B Subordinate Voting Shares stock.

FSD Pharma Inc. (HUGE) is a biopharmaceutical innovator advancing cannabinoid-based therapies and pharmaceutical-grade cannabis production. This news hub provides investors and industry professionals with essential updates on clinical developments, strategic partnerships, and regulatory milestones.

Access timely press releases covering clinical trial progress for neurodegenerative treatments, product commercialization efforts including alcohol misuse solutions, and research collaborations shaping the future of medical cannabis. Our curated updates ensure you stay informed about developments impacting FSD Pharma's position in biotech innovation.

Key coverage areas: Phase trial results for Lucid-MS multiple sclerosis treatment, unbuzzd™ market expansion, intellectual property updates, and manufacturing capacity enhancements. All content is verified through primary sources to maintain accuracy.

Bookmark this page for centralized access to FSD Pharma's latest announcements, analyst commentary, and progress reports on therapies targeting autoimmune disorders and neurological conditions.

News

FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)

Rhea-AI Summary
FSD Pharma provides an update on Celly Nu's anticipated launch of unbuzzd(TM), a scientifically formulated beverage product designed to support alcohol metabolism and alertness. Celly Nu partners with BevSource for production and distribution in the US. The partnership includes various services to ensure a successful launch. The product, unbuzzd(TM), features a blend of vitamins, minerals, and botanical extracts. Industry veterans like Gerry David and John Duffy lead the project, supported by Kevin Harrington.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
none
-
News

FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products

Rhea-AI Summary
FSD Pharma, a biopharmaceutical company, expands its pipeline to include potential weight loss and liver health formulations and products. The company is investigating ingredients and dietary supplements to promote weight loss, liver health, and faster alcohol metabolism. This move aims to address metabolic disorders and create a new product line.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.8%
Tags
none
-
News

FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption

Rhea-AI Summary
FSD Pharma increases investment in Celly Nutrition Corp. to launch a product expediting alcohol metabolism and recovery. The loan agreement allows for the principal increase by $300,000, deferral of interest payments, and potential conversion to common shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.4%
Tags
none
News

FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Rhea-AI Summary
FSD Pharma Inc. received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, giving them a 180-day compliance period to meet the requirement or face potential delisting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
none
-
News

FSD Pharma Announces Filing of Year-End 2023 Results

Rhea-AI Summary
FSD Pharma Inc. (HUGE) announces the filing of audited annual financial results for the fourth quarter and full year ended December 31, 2023, along with the Annual Report on 20-F for the same period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.18%
Tags
none
-
News

FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults

Rhea-AI Summary
FSD Pharma Inc. announces a partnership with iNGENu CRO Pty to conduct a Phase 1 clinical study on Lucid-21-302, a novel compound for treating multiple sclerosis. The compound has shown promise in preclinical models for preventing demyelination, a key factor in MS and other neurogenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
clinical trial
News

FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)

Rhea-AI Summary
FSD Pharma Inc. announces the submission of a Clinical Trial Application for a Phase-1b clinical trial to assess the safety and efficacy of unbuzzd™ in Healthy Volunteers in an Induced State of Alcohol Intoxication. The trial aims to evaluate the potential benefits of unbuzzd™, a dietary supplement product, in enhancing cognition, replenishing cofactors needed for alcohol metabolism, and accelerating the rate of alcohol metabolism in the body. The company is working closely with Australian partners and an ethics committee for the project. John Duffy, CEO of Celly Nutrition, highlighted the product's ability to restore mental alertness and improve cognition post-alcohol consumption, emphasizing the science-based approach. The involvement of industry veterans from companies like Coca-Cola and Celsius Energy drink adds credibility to the project.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.58%
Tags
clinical trial
-
News

FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum

Rhea-AI Summary
FSD Pharma announces positive results from Phase-1 clinical study on Lucid-21-302 for Multiple Sclerosis treatment at ACTRIMS 2024 Forum.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.06%
Tags
none
-
News

FSD Pharma Announces Debt Settlement

Rhea-AI Summary
FSD Pharma Inc. settles $637,650 in debts through share issuance and grants RSUs to consultants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.24%
Tags
none
News

FSD Pharma Signs Agreement With Ingenu CRO to Conduct a Clinical Trial To Determine the Safety and Efficacy Effects of its Proprietary Blend Beverage unbuzzd(TM)

Rhea-AI Summary
FSD Pharma Inc. announced a partnership with Ingenu CRO Pty Ltd to conduct a study on unbuzzd™, a dietary supplement that may help individuals sober up faster from alcohol intoxication. The company aims to verify the product's efficacy and accelerate alcohol metabolism. Celly Nutrition Corp. holds exclusive rights for recreational sales, while FSD Pharma develops a medical product for hospitals and frontline workers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
Stock HUGE logo
FSD Pharma Inc. Class B Subordinate Voting Shares

Nasdaq:HUGE

HUGE Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

HUGE Stock Data

63.71k
42.75M
9.74%
2.69%
0.38%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Canada
Toronto